These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8665623)

  • 1. [Drug monitoring].
    Royer RJ
    Bull Soc Sci Med Grand Duche Luxemb; 1995; 132(3):33-4. PubMed ID: 8665623
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug monitoring in Tunisia: organization and objectives].
    Daghfous R; Elaidi S; Loueslati MH; Srairi S; Lakhal M; Belkahia C
    Tunis Med; 1994 Feb; 72(2):83-6. PubMed ID: 7974826
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.
    Spigset O; Hedenmalm K
    Pharmacotherapy; 1997; 17(2):348-52. PubMed ID: 9085327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists' role in reporting adverse drug reactions in an international perspective.
    van Grootheest K; Olsson S; Couper M; de Jong-van den Berg L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):457-64. PubMed ID: 15269929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center.
    Lindquist M; Edwards IR
    J Rheumatol; 2001 May; 28(5):1180-7. PubMed ID: 11361210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presenting the case for an immunization safety surveillance system.
    Darwish AA
    Bull World Health Organ; 2000; 78(2):216. PubMed ID: 10743287
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reporting system for adverse drug reactions and infections].
    Hashiguchi M; Mochizuki M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():67-72. PubMed ID: 18074519
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the most of spontaneous adverse drug reaction reporting.
    Waller PC
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):320-3. PubMed ID: 16611209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database.
    Ståhl M; Lindquist M; Edwards IR; Brown EG
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):355-63. PubMed ID: 15170764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reaction reporting and monitoring: role of practising physicians.
    Bhatia RS; Sibia SS
    J Assoc Physicians India; 2000 Aug; 48(8):852. PubMed ID: 11273490
    [No Abstract]   [Full Text] [Related]  

  • 14. [Classification and profile of adverse drug effects].
    Cordonnier M
    Bull Soc Belge Ophtalmol; 2007; (304):15-6. PubMed ID: 17718223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of pharmacovigilance system in Ukraine: first results.
    Stefanov O; Sharayeva M; Jajtchenja V
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):197-9. PubMed ID: 15072120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.
    Bate A; Lindquist M; Orre R; Edwards IR; Meyboom RH
    Eur J Clin Pharmacol; 2002 Oct; 58(7):483-90. PubMed ID: 12389072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Uppsala monitoring centre: a review of viewpoint part 1 and part 2.
    Hugman B
    Drug Saf; 2005; 28(7):645-6. PubMed ID: 15963009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reaction monitoring in India.
    Kshirsagar NA; Karande SC; Potkar CN
    J Assoc Physicians India; 1993 Jun; 41(6):374-6. PubMed ID: 8005977
    [No Abstract]   [Full Text] [Related]  

  • 19. Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice.
    Stelfox HT; Ahmed SB; Fiskio J; Bates DW
    Clin Pharmacol Ther; 2004 Jan; 75(1):110-22. PubMed ID: 14749697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adverse drug reaction: a clinical opportunity for pharmacists.
    Miller JD
    Hosp Pharm; 1995 Sep; 30(9):769-73. PubMed ID: 10151281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.